3 stories
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that selectively stimulates GH release through the ghrelin receptor. It has a long history in the research-peptide and wellness market, often paired with CJC-1295 in 'GH-restoration' protocols at peptide clinics.
The regulatory picture matches the broader research-peptide pattern. Ipamorelin sits on the FDA's Section 503A bulks list discussions, has been the subject of state medical board enforcement against peptide clinics, and was on the ProPublica-reported list of injectable peptides covered by the FDA's 2023 effective ban that RFK Jr. is reportedly preparing to reverse.
Clinical evidence for advertised wellness claims (anti-aging, body composition, recovery) remains thin. Stories here cover the regulatory action and any registered human trials. See #cjc-1295 and #sermorelin for adjacent tags.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.